OpenAlex
PricingAboutJobs
Log inGet started
Work

Emerging MEK inhibitors

HTML

Year: 2010
Type: review
Source: Expert Opinion on Emerging Drugs
DOI: 10.1517/14728210903282760
Authors: James A McCubrey, Linda S Steelman, Steven L Abrams, William H Chappell, Suzanne Russo, Roger Ove, Michele Milella, Agostino Tafuri, Paolo Lunghi, Antonio Bonati, Franca Stivala, Ferdinando Nicoletti, Massimo Libra, Alberto M Martelli, Giuseppe Montalto, Melchiorre Cervello
Institutions: East Carolina University, Instituto Nazionale Tumori Regina Elena, Sapienza University of Rome, University of Parma, Ospedale di Parma, University of Catania, University of Bologna, University of Palermo, Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy, National Research Council
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: MEK inhibitors, RAS/MAPK pathway, RAF inhibitors, cancer therapy, cell proliferation, apoptosis, BRAF mutation, RAS mutations, combination therapy, cancer stem cells, cellular aging, targeted therapy
SDG: Good health and well-being

Open Access status: closed

Funder: U.S. Public Health Service
Award: G3509830000
OpenAlex ID: W2134295475
FWCI: 0.824
Cites: 109
Cited by: 63
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security